---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-206325"
form_type: "8-K"
ticker: "CDNA"
cik: "0001217234"
company_name: "CareDx, Inc."
filed_at: "2021-07-01T23:59:59+00:00"
generated_at: "2026-06-30T07:52:09.351760+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# CareDx appoints Dr. Hannah Valantine to board; co-inventor of AlloSure technology

## Summary
- Dr. Hannah Valantine appointed as Class I director effective July 1, 2021.
- She is Professor of Medicine at Stanford and former NIH Chief Scientific Officer for Workforce Diversity.
- She co-invented the donor-derived cell-free DNA technology (AlloSure) for transplant rejection monitoring.
- Initial equity grants: option and RSU each with $150,000 grant-date fair value; annual cash retainer $40,000.
- She also serves on board of Pacific Biosciences of California (Nasdaq: PACB) since June 2021.

## SEC filing metadata
- accession: 0001193125-21-206325
- form_type: 8-K
- ticker: CDNA
- cik: 0001217234
- company_name: CareDx, Inc.
- filed_at: 2021-07-01T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1217234/000119312521206325/0001193125-21-206325-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1217234/000119312521206325/d196856d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-206325
- JSON: https://secwatch.observer/filing/0001193125-21-206325.json
- Plain text: https://secwatch.observer/filing/0001193125-21-206325.txt

## Key facts
- Executive change
  Hannah A. Valantine was appointed as Class I Director at CareDx, Inc..
  - Action: appointed
  - Role: Class I Director
  source text: On June 30, 2021, the board of directors (the “Board”) of CareDx, Inc. (the “Company”) appointed Hannah A. Valantine, M.D. as a Class I director of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1217234/000119312521206325/0001193125-21-206325-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.